Boundless Bio Inc.

Clinical-stage precision oncology company developing ecDNA-directed therapies (ecDTx) for oncogene-amplified cancers, built on its proprietary Spyglass platform. Following a 2025 portfolio prioritization that paused the BBI-355/BBI-825 POTENTIATE combination trial, the lead program is BBI-940, an oral Kinesin degrader entering the Phase 1 KOMODO-1 trial in ER+/HER2- and TNBC-LAR breast cancer.